Login

Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

February 22, 2024
BioUtah News
Utah Legislative Recap: February 23, 2024

Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create and […]

February 22, 2024
BioUtah News
EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 BillionCatheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated […]

February 22, 2024
BioUtah News
Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

SALT LAKE CITY, UT, February 22, 2024 (BusinessWire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony […]

February 22, 2024
BioUtah News
February 22, 2024
BioUtah News
Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

Recipients’ research focused on melanoma diagnosis, treatment response in advanced NSCLC, and bypassing common hurdles in NSCLC diagnosis and treatment

February 22, 2024
BioUtah News
Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership

Pharma and biotech customers distinguish excellence in capabilities, compatibility, expertise, quality and reliability

February 15, 2024
BioUtah News
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience […]

February 15, 2024
BioUtah News
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65and $15.35 per Share in the Late Spring or Early […]

February 15, 2024
BioUtah News
PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year   OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, […]

February 15, 2024
BioUtah News
Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, […]

February 15, 2024
BioUtah News
Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the […]

February 15, 2024
BioUtah News
Utah Legislative Recap – February 15, 2024

Utah Legislative Recap – Updated February 15, 2024

February 9, 2024
BioUtah News
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd

LONDON and SALT LAKE CITY, February 9, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on February 8, 2024 the Centers for Medicare and Medicaid Services (“CMS”) published a draft Local Coverage Determination (“LCD”) for the Company’s KidneyIntelX and kidneyintelX.dkd testing. The draft LCD can be accessed at https://www.cms.gov/medicare-coverage-database/. The established Medicare price […]

February 8, 2024
BioUtah News
Utah Legislative Recap, Feb. 9, 2024

Funding Requests   Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]

February 8, 2024
BioUtah News
2024 Life Sciences Day on the Hill Recap

Utah’s vibrant life sciences industry was on full display February 7 as part of BioUtah’s “Life Sciences Day on the Hill”. The event, a collarboration with the Governor’s Office of Economic Opportunity, (GOEO) was held at the state capitol. 29 companies exhibited their innovative technologies in the capitol rotunda, which provided legislators the opportunity to […]

February 8, 2024
BioUtah News
Eris Biotech accepted to Y Combinator

Eris Biotech accepted to Y Combinator

February 8, 2024
BioUtah News
Clene Inc. Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

February 8, 2024
BioUtah News
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

February 8, 2024
BioUtah News
Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation

This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)

February 8, 2024
BioUtah News
AdvaMed Announces New Chair of State Medtech Alliance

AdvaMed Announces New Chair of State Medtech Alliance

February 1, 2024
Policy News
Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics

Funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, Jan. 31, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the completion […]

February 1, 2024
BioUtah News
AI Utah Annouces Inaugural AI Utah 100 List

AI Utah Annouces Inaugural AI Utah 100 List

February 1, 2024
BioUtah News
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

February 1, 2024
BioUtah News
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health

Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health